Turgut Aksoy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Turgut Aksoy has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Ahmet Acet
Department of Pharmacology, Faculty of Medicine, Inonu University, Malatya, Turkey
1 shared publication - Akın ARSLAN
SAKARYA UNİVERSİTESİ EĞİTİM VE ARAŞ. HASTANES
1 shared publication - Ayşegül Yabacı Tak
Department of Biostatistics and Medical Informatics, Bezmialem Vakif University, Istanbul, Turkey
1 shared publication - Canan Kelten Talu1 shared publication
- Canan Yasar
Department of Periodontology, Faculty of Dentistry, Bezmialem Vakif University , Adnan Menderes Vatan Avenue, Nu:113, 34093, Fatih, Istanbul
1 shared publication - Didem Can Trabulus
Department of General Surgery, School of Medicine, Bahçeşehir University, 34734 Istanbul, Turkey
1 shared publication
Latest Publications
- 12 August 2025
- Published by Springer Nature in Clinical Oral Investigations
- Vol. 29 (9) , 1-11
Annexin A1 levels in polycystic ovary syndrome: impact of professional mechanical plaque removal
Objective This study aimed to investigate the local inflammatory profile in women with polycystic ovary syndrome (PCOS) by assessing interleukin (IL)-6, IL-10, and annexin A1 (ANXA1) levels in saliva and gingival crevicular fluid (GCF), and to compare the clinical and biochemical responses to proffessional mechanical plaque removal (PMPR) between women with PCOS and systemically healthy individuals. Methods Eighty women were allocated into four groups: (1) PCOS-healthy periodontium (PCOSH), (2) PCOS-gingivitis (PCOSG), (3) systemically healthy-gingivitis (SG), (4) systemically and periodontally healthy (SH). Clinical periodontal parameters and saliva/GCF samples were collected at baseline and 6 weeks after PMPR. IL-6, IL-10, and ANXA1 levels were measured by ELISA. Data were analyzed using one-way ANOVA, Kruskal-Wallis tests, and multiple linear regression. Results Both gingivitis groups showed comparable clinical improvements and significant reductions in salivary IL-6 levels and the IL-6/IL-10 ratio following PMPR, independent of PCOS status. Notably, GCF ANXA1 levels increased in PCOSG but decreased in SG. In the PCOSG group, baseline levels of estradiol and follicle-stimulating hormone were significant predictors of changes in GCF ANXA1, as indicated by multiple regression analysis. Conclusion PMPR may lead to similar clinical and local biochemical outcomes in patients with gingivitis, regardless of PCOS status. ANXA1 may have a specific role in modulating gingival inflammation in women with PCOS. Clinical relevance This study highlights the importance of managing gingivitis in women with PCOS, suggesting that periodontal treatment may result in comparable improvements. Additionally, the findings suggest a potential modulatory role for ANXA1 in the periodontal inflammatory response associated with PCOS.
- 12 August 2025
- Published by Springer Nature in Clinical Oral Investigations
- Vol. 29 (9) , 1-11
Annexin A1 levels in polycystic ovary syndrome: impact of professional mechanical plaque removal
Objective This study aimed to investigate the local inflammatory profile in women with polycystic ovary syndrome (PCOS) by assessing interleukin (IL)-6, IL-10, and annexin A1 (ANXA1) levels in saliva and gingival crevicular fluid (GCF), and to compare the clinical and biochemical responses to proffessional mechanical plaque removal (PMPR) between women with PCOS and systemically healthy individuals. Methods Eighty women were allocated into four groups: (1) PCOS-healthy periodontium (PCOSH), (2) PCOS-gingivitis (PCOSG), (3) systemically healthy-gingivitis (SG), (4) systemically and periodontally healthy (SH). Clinical periodontal parameters and saliva/GCF samples were collected at baseline and 6 weeks after PMPR. IL-6, IL-10, and ANXA1 levels were measured by ELISA. Data were analyzed using one-way ANOVA, Kruskal-Wallis tests, and multiple linear regression. Results Both gingivitis groups showed comparable clinical improvements and significant reductions in salivary IL-6 levels and the IL-6/IL-10 ratio following PMPR, independent of PCOS status. Notably, GCF ANXA1 levels increased in PCOSG but decreased in SG. In the PCOSG group, baseline levels of estradiol and follicle-stimulating hormone were significant predictors of changes in GCF ANXA1, as indicated by multiple regression analysis. Conclusion PMPR may lead to similar clinical and local biochemical outcomes in patients with gingivitis, regardless of PCOS status. ANXA1 may have a specific role in modulating gingival inflammation in women with PCOS. Clinical relevance This study highlights the importance of managing gingivitis in women with PCOS, suggesting that periodontal treatment may result in comparable improvements. Additionally, the findings suggest a potential modulatory role for ANXA1 in the periodontal inflammatory response associated with PCOS.
- Open Access
- 25 October 2023
- Published by Journal of Biotechnology and Strategic Health Research in JOURNAL OF BIOTECHNOLOGY AND STRATEGIC HEALTH RESEARCH
- Vol. 7 (3) , 192-200
Myocardial Protection With Remote Ischemic Preconditioning In Congenital Heart Surgery: Does It Deliver What Is Expected?
Objective: The discovery of the protective effects of antioxidant agents on organ functions enabled this system to be tested artificially. The impact of remote ischemic preconditioning (RIPC) on surgical clinical outcomes in patients with congenital heart defects is unclear. This study investigated the early consequences of ischemic preconditioning on cardiac protection. Methods: The study was designed prospectively. Cuffs were applied to one leg of patients in Group 1 (RIPC) after induction of anesthesia in three cycles (5 min inflation followed by 5 min reperfusion) to precondition ischemia-reperfusion. Antioxidant and cardiac marker levels were recorded in blood samples. Results: The patients' surgical median age was 19.1 months (IQR= 3.7- 57.7 months) in Group 1 (RIPC) and 16.7 months (IQR= 7.8- 35.9 months) in Group 2 (Control). The patients' median follow-up period was 58.3 months (IQR= 54.3- 62.1 months) in group 1 and 37.1 months (IQR= 34.8- 41.7 months) in group 2. Hospital mortality was in 7 (10.4%) patients. There was no late mortality. There was a significant difference between the groups in terms of Superoxide Dismutase (SOD) and Malondialdehyde (MDA) levels (p<005). Conclusion: The effects of ischemic preconditioning on cardiac protection have not been proven yet. Especially in congenital cardiac patients, chronic stimuli such as hypoxia and cyanosis or drugs used before surgery may affect the study’s results. Although there is no significant difference in mortality in these patients, a positive effect on the length of hospital stay is promising.
- 25 October 2023
- Published by Journal of Biotechnology and Strategic Health Research in JOURNAL OF BIOTECHNOLOGY AND STRATEGIC HEALTH RESEARCH
- Vol. 7 (3) , 192-200
Open AccessMyocardial Protection With Remote Ischemic Preconditioning In Congenital Heart Surgery: Does It Deliver What Is Expected?
Objective: The discovery of the protective effects of antioxidant agents on organ functions enabled this system to be tested artificially. The impact of remote ischemic preconditioning (RIPC) on surgical clinical outcomes in patients with congenital heart defects is unclear. This study investigated the early consequences of ischemic preconditioning on cardiac protection. Methods: The study was designed prospectively. Cuffs were applied to one leg of patients in Group 1 (RIPC) after induction of anesthesia in three cycles (5 min inflation followed by 5 min reperfusion) to precondition ischemia-reperfusion. Antioxidant and cardiac marker levels were recorded in blood samples. Results: The patients' surgical median age was 19.1 months (IQR= 3.7- 57.7 months) in Group 1 (RIPC) and 16.7 months (IQR= 7.8- 35.9 months) in Group 2 (Control). The patients' median follow-up period was 58.3 months (IQR= 54.3- 62.1 months) in group 1 and 37.1 months (IQR= 34.8- 41.7 months) in group 2. Hospital mortality was in 7 (10.4%) patients. There was no late mortality. There was a significant difference between the groups in terms of Superoxide Dismutase (SOD) and Malondialdehyde (MDA) levels (p<005). Conclusion: The effects of ischemic preconditioning on cardiac protection have not been proven yet. Especially in congenital cardiac patients, chronic stimuli such as hypoxia and cyanosis or drugs used before surgery may affect the study’s results. Although there is no significant difference in mortality in these patients, a positive effect on the length of hospital stay is promising.
- 9 September 2020
- Published by Galenos Yayinevi in Istanbul Medical Journal
- Vol. 21 (5) , 355-361
Significantly Lower Serum Adiponectin Levels in the Postmenopausal Age may be Specific for Breast Cancer Risk
- 9 September 2020
- Published by Galenos Yayinevi in Istanbul Medical Journal
- Vol. 21 (5) , 355-361
Significantly Lower Serum Adiponectin Levels in the Postmenopausal Age may be Specific for Breast Cancer Risk
- 1 October 1997
- Published by Elsevier in Pharmacological Research
- Vol. 36 (4) , 299-304
THE ROLE OF PROSTAGLANDIN SYNTHESIS STIMULATION IN THE PROTECTIVE EFFECT OF CAPTOPRIL ON ISCHAEMIA-REPERFUSION ARRHYTHMIAS IN RATSIN VIVO
- 1 October 1997
- Published by Elsevier in Pharmacological Research
- Vol. 36 (4) , 299-304
THE ROLE OF PROSTAGLANDIN SYNTHESIS STIMULATION IN THE PROTECTIVE EFFECT OF CAPTOPRIL ON ISCHAEMIA-REPERFUSION ARRHYTHMIAS IN RATSIN VIVO